Strides Pharma teams up with Ennaid Therapeutics to manufacture COVID-19 drug
Strides Pharma teams up with Ennaid Therapeutics to manufacture COVID-19 drug
15 June 2021 | News
Ennaid Therapeutics will produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19
Image Credit: shutterstock.com
Bengaluru-based Strides Pharma Science has announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with US-based Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.
Ennaid’s partnership with discovery scientists at Universidad Católica de Murcia (UCAM), identified a therapeutic target to treat COVID‐19 using artificial intelligence drug discovery platforms.